[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024; 74, 229−63.
[2] WHO. Cancer today. https://gco.iarc.who.int/today/. [2025-02] (查阅网上资料,请补充完整引用日期信息,请确认)
[3] Zeng HM, Chen WQ, Zheng RS, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018; 6, e555−67. doi:  10.1016/S2214-109X(18)30127-X
[4] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018; 391, 1023−75. doi:  10.1016/S0140-6736(17)33326-3
[5] He J, Chen WQ, Li ZS, et al. China guideline for the screening, early detection and early treatment of gastric cancer (2022, Beijing). Chin J Oncol, 2022; 44, 634−66. (In Chinese)
[6] Januszewicz W, Witczak K, Wieszczy P, et al. Prevalence and risk factors of upper gastrointestinal cancers missed during endoscopy: a nationwide registry-based study. Endoscopy, 2022; 54, 653−60. doi:  10.1055/a-1675-4136
[7] Ribatti D, Tamma R. A revisited concept. Tumors: wounds that do not heal. Crit Rev Oncol/Hematol, 2018; 128, 65−9. doi:  10.1016/j.critrevonc.2018.05.016
[8] Alberts SR, Cervantes A, van de Velde CJH. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol, 2003; 14, ii31−6. doi:  10.1093/annonc/mdg726
[9] Pih GY, Gong EJ, Choi JY, et al. Associations of serum lipid level with gastric cancer risk, pathology, and prognosis. Cancer Res Treat, 2021; 53, 445−56. doi:  10.4143/crt.2020.599
[10] Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol, 2013; 13, 34−45. doi:  10.1038/nri3345
[11] Emoto S, Ishigami H, Yamashita H, et al. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer, 2012; 15, 154−61. doi:  10.1007/s10120-011-0091-8
[12] Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer, 2014; 17, 26−33. doi:  10.1007/s10120-013-0259-5
[13] Virji MA, Mercer DW, Herberman RB. Tumor markers in cancer diagnosis and prognosis. CA Cancer J Clin, 1988; 38, 104−26.
[14] Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective. World J Gastroenterol, 2018; 24, 2818−32. doi:  10.3748/wjg.v24.i26.2818
[15] Mucci LA, Hjelmborg JB, Harris JR, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA, 2016; 315, 68−76.
[16] Yan CW, Zhu M, Ding YB, et al. Meta-analysis of genome-wide association studies and functional assays decipher susceptibility genes for gastric cancer in Chinese populations. Gut, 2020; 69, 641−51. doi:  10.1136/gutjnl-2019-318760
[17] Jin GF, Lv J, Yang M, et al. Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study. Lancet Oncol, 2020; 21, 1378−86. doi:  10.1016/S1470-2045(20)30460-5
[18] Cooper RS. Gene–environment interactions and the etiology of common complex disease. Ann Intern Med, 2003; 139, 437−40. doi:  10.7326/0003-4819-139-5_Part_2-200309021-00011
[19] Wang L, Liu J, Zhu M, et al. Cohort profile: the Taihu Biobank of Tumour Biomarkers (TBTB) study in Wuxi, China. Int J Epidemiol, 2024; 53, dyad173. doi:  10.1093/ije/dyad173
[20] Duan YT, Xu YH, Dou Y, et al. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol, 2025; 18, 10. doi:  10.1186/s13045-024-01654-2
[21] Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw, 2010; 33, 1−22.
[22] Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 1982; 143, 29−36.
[23] Kerr KF, Brown MD, Zhu KH, et al. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol, 2016; 34, 2534−40. doi:  10.1200/JCO.2015.65.5654
[24] Debray TPA, Damen JAAG, Snell KIE, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ, 2017; 356, i6460. doi:  10.1136/bmj.i6460
[25] Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA, 2017; 318, 1377−84.
[26] Matsuoka T, Yashiro M. Bioinformatics analysis and validation of potential markers associated with prediction and prognosis of gastric cancer. Int J Mol Sci, 2024; 25, 5880. doi:  10.3390/ijms25115880
[27] Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - “ABC method. ” Proc Japan Acad Ser B, 2011; 87, 405−14. doi:  10.2183/pjab.87.405
[28] Tu HK, Sun LP, Dong X, et al. A serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: a multi-phase study. Am J Gastroenterol, 2017; 112, 704−15. doi:  10.1038/ajg.2017.55
[29] Cai QC, Zhu CP, Yuan Y, et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study. Gut, 2019; 68, 1576−87. doi:  10.1136/gutjnl-2018-317556
[30] Boicean A, Boeras I, Birsan S, et al. In pursuit of novel markers: unraveling the potential of miR-106, CEA and CA 19-9 in gastric adenocarcinoma diagnosis and staging. Int J Mol Sci, 2024; 25, 7898. doi:  10.3390/ijms25147898
[31] Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the general population nutrition intervention trial cohort. Gut, 2009; 58, 636−42. doi:  10.1136/gut.2008.168641
[32] Xu YT, Zhang PS, Zhang KD, et al. The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. Biochim Biophys Acta (BBA)-Rev Cancer, 2021; 1876, 188634. doi:  10.1016/j.bbcan.2021.188634
[33] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell, 2010; 140, 883−99. doi:  10.1016/j.cell.2010.01.025
[34] Wang J, Erlacher M, Fernandez-Orth J. The role of inflammation in hematopoiesis and bone marrow failure: what can we learn from mouse models? Front Immunol, 2022; 13, 951937.
[35] Li GS, Huang T, Li JX, et al. Correlation between hemoglobin and the risk of common malignant tumors: a 1999-2020 retrospective analysis and causal association analysis. BMC Cancer, 2024; 24, 755. doi:  10.1186/s12885-024-12495-0
[36] Wu JP, Yang YF, Cheng L, et al. GCdiscrimination: identification of gastric cancer based on a milliliter of blood. Brief Bioinform, 2021; 22, 536−44. doi:  10.1093/bib/bbaa006
[37] Wang HY, Ding YM, Zhao SJ, et al. Establishment and validation of a nomogram model for early diagnosis of gastric cancer: a large-scale cohort study. Front Oncol, 2024; 14, 1463480. doi:  10.3389/fonc.2024.1463480
[38] Kitahara CM, de González AB, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol, 2011; 29, 1592−8. doi:  10.1200/JCO.2010.31.5200
[39] Asano K, Kubo M, Yonemoto K, et al. Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer, 2008; 122, 909−14. doi:  10.1002/ijc.23191
[40] Iso H, Ikeda A, Inoue M, et al. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer, 2009; 125, 2679−86. doi:  10.1002/ijc.24668
[41] Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol, 2015; 16, e60−70. doi:  10.1016/S1470-2045(14)71016-2
[42] Huntley C, Torr B, Sud A, et al. Utility of polygenic risk scores in UK cancer screening: a modelling analysis. Lancet Oncol, 2023; 24, 658−68. doi:  10.1016/S1470-2045(23)00156-0
[43] Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet, 2005; 6, 287−98.